

# 4DMedical strengthens executive group: experienced MedTech CFO appointed

24 June 2022

## Highlights

- 4DMedical has appointed experienced ASX-listed MedTech CFO Simon Glover as the Company's new CFO
- Mr Glover has significant corporate experience in relation to commercialisation, business strategy, cashflow management and a track record of driving revenue growth
- Mr Glover has served in senior finance leadership roles for MedAdvisor Limited (ASX: MDR), Coles Group (ASX:COL), Tabcorp Holdings Limited (ASX:TAH), Jetstar (ASX:QAN) and KPMG
- 4DMedical's exiting CFO Heath Lee will remain at 4DMedical until 29 July to ensure the smooth transition of his responsibilities to Mr Glover

**Melbourne, Australia, 24 June 2022:** Respiratory imaging technology company 4DMedical Limited (ASX:4DX, "4DMedical", or the "Company") is pleased to announce it has appointed experienced ASX-listed MedTech CFO Simon Glover as the Company's new CFO effective 25<sup>th</sup> July 2022.

Mr Glover has significant corporate experience in relation to commercialisation, business strategy, cashflow management and a track record of driving revenue growth. He joins 4DMedical after three years serving MedAdvisor Limited (ASX: MDR) in the role of CFO.

Mr Glover is in a unique position to leverage his experience at MedAdvisor, a SaaS MedTech with global operations across the US, UK, Asia, and Australia. Mr Glover has also held senior finance leadership roles for Coles Group (ASX:COL), Tabcorp Holdings Limited (ASX:TAH), Jetstar (ASX:QAN) and KPMG.

4DMedical's exiting CFO, Heath Lee, will remain at 4DMedical until 29 July to ensure the smooth transition of his responsibilities to Mr Glover.

## Commenting on the CFO transition, 4DMedical Managing Director & CEO Andreas Fouras said:

"After a comprehensive executive search which attracted several exceptional candidates, 4DMedical is excited to have Simon join our executive group as CFO. As 4DMedical continues its commercialisation journey, a fresh perspective, bolstered by significant and relevant industry experience, is welcomed. We look forward to Simon making a meaningful contribution as we accelerate commercialisation of our technology.

On behalf of the Board, I would like to thank Heath for his commitment to 4DMedical over the past six years, initially as a Board member and more recently as CFO, where he played a significant role in the IPO. Heath is well regarded having created a high performing finance and administration team, and we wish him all the best with his future endeavours."



**Commenting on his new role, incoming 4DMedical CFO Simon Glover said:**

“I am very much looking forward to commencing in the role of CFO for 4DMedical and supporting the Company to commercialise its revolutionary technology. I have operated at the most senior level in professional services across multiple industries, including SaaS MedTech, and approach my roles with a highly commercial results-driven focus. I believe 4DMedical has an extremely exciting future and I will be working hard to contribute through a high level of strategic insight, leadership and integrity.”

**-ENDS-**

Authorised by the 4DMedical Board of Directors.

**Contacts**

***Corporate***

Melanie Leydin  
Company Secretary  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

***Media***

Julia Maguire  
+ 61 419 815 386  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**About 4DMedical**

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand lung function of patients with respiratory diseases.

Through its flagship patented XV Technology™, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical’s FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS™), which is the first and only modality that can dynamically quantify ventilation throughout the lungs. It additionally exposes the patient to lower levels of radiation relative to other diagnostic methods, a clear advantage when disease progression and therapeutic effectiveness need to be regularly monitored.

XV LVAS™ reports are prepared utilising 4DMedical’s Software as a Service delivery model using existing hospital imaging equipment or the company’s own revolutionary XV Scanner.

To learn more, please visit: [www.4dmedical.com](http://www.4dmedical.com)